-
Sector Analysis
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Post-Traumatic Stress Disorder (PTSD) Marketed and Pipeline Drugs Overview In the seven major pharmaceutical markets (7MM: France, Germany, Italy, Japan, Spain, UK and the US), GlobalData epidemiologists estimated more than 1.02 million acute diagnosed prevalent cases for PTSD in 2023. Post-Traumatic Stress Disorder (PTSD) is a mental disorder that can occur after experiencing a traumatic event. Characterized by symptoms typical of anxiety disorders such as irritability, sleep disturbances, disrupted concentration, and increased heart rate, PTSD is distinguished by the patient...
-
Product Insights
Post-Traumatic Stress Disorder Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Traumatic Stress Disorder (PTSD) Clinical Trials Market Report Overview The PTSD clinical trial market research report provides an overview of PTSD clinical trials scenario. This report provides top line data relating to the clinical trials on PTSD. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.